Bartlett & Co’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $15.1M | Sell |
151,046
-2,000
| -1% | -$193K | 0.25% | 76 |
|
|
2023
Q3 | $15.6M | Sell |
153,046
-2,722
| -2% | -$276K | 0.28% | 73 |
|
|
2023
Q2 | $15.7M | Sell |
155,768
-11,825
| -7% | -$1.18M | 0.27% | 75 |
|
|
2023
Q1 | $15.4M | Sell |
167,593
-10,278
| -6% | -$898K | 0.3% | 73 |
|
|
2022
Q4 | $16.1M | Sell |
177,871
-3,394
| -2% | -$286K | 0.32% | 73 |
|
|
2022
Q3 | $13.8M | Sell |
181,265
-2,848
| -2% | -$236K | 0.3% | 75 |
|
|
2022
Q2 | $15.6M | Sell |
184,113
-31,329
| -15% | -$2.75M | 0.32% | 73 |
|
|
2022
Q1 | $18.9M | Sell |
215,442
-543
| -0.3% | -$47K | 0.33% | 73 |
|
|
2021
Q4 | $18.9M | Sell |
215,985
-4,938
| -2% | -$410K | 0.32% | 71 |
|
|
2021
Q3 | $18.1M | Sell |
220,923
-1,110
| -0.5% | -$99.9K | 0.34% | 70 |
|
|
2021
Q2 | $20.3M | Sell |
222,033
-7,837
| -3% | -$698K | 0.39% | 69 |
|
|
2021
Q1 | $19.6M | Sell |
229,870
-6,832
| -3% | -$613K | 0.4% | 68 |
|
|
2020
Q4 | $22.4M | Sell |
236,702
-4,084
| -2% | -$357K | 0.48% | 62 |
|
|
2020
Q3 | $20.9M | Buy |
240,786
+6,215
| +3% | +$538K | 0.49% | 61 |
|
|
2020
Q2 | $20.5M | Sell |
234,571
-3,092
| -1% | -$267K | 0.54% | 56 |
|
|
2020
Q1 | $19.6M | Buy |
+237,663
| New | +$21.2M | 0.6% | 50 |
|
|
2019
Q3 | $21.5M | Sell |
247,460
-9,885
| -4% | -$888K | 0.56% | 54 |
|
|
2019
Q2 | $23.5M | Sell |
257,345
-242,823
| -49% | -$20.6M | 0.88% | 43 |
|
|
2019
Q1 | $43.1M | Sell |
500,168
-3,505
| -0.7% | -$281K | 1.65% | 18 |
|
|
2018
Q4 | $38.7M | Sell |
503,673
-3,957
| -0.8% | -$308K | 1.65% | 17 |
|
|
2018
Q3 | $39.2M | Sell |
507,630
-1,461
| -0.3% | -$108K | 1.47% | 19 |
|
|
2018
Q2 | $34.5M | Sell |
509,091
-12,478
| -2% | -$861K | 1.4% | 23 |
|
|
2018
Q1 | $37.8M | Sell |
521,569
-2,646
| -0.5% | -$201K | 1.56% | 17 |
|
|
2017
Q4 | $39.4M | Sell |
524,215
-3,743
| -0.7% | -$282K | 1.57% | 20 |
|
|
2017
Q3 | $40.6M | Buy |
527,958
+8,089
| +2% | +$611K | 1.7% | 17 |
|
|
2017
Q2 | $38.9M | Sell |
519,869
-360
| -0.1% | -$25.5K | 1.75% | 16 |
|
|
2017
Q1 | $34.6M | Buy |
520,229
+1,771
| +0.3% | +$118K | 1.57% | 19 |
|
|
2016
Q4 | $33.8M | Buy |
518,458
+15,788
| +3% | +$1.02M | 1.6% | 20 |
|
|
2016
Q3 | $35.6M | Buy |
502,670
+4,137
| +0.8% | +$301K | 1.72% | 16 |
|
|
2016
Q2 | $36.9M | Buy |
498,533
+5,881
| +1% | +$406K | 1.82% | 14 |
|
|
2016
Q1 | $32M | Buy |
492,652
+10,302
| +2% | +$701K | 1.6% | 17 |
|
|
2015
Q4 | $37.2M | Sell |
482,350
-1,462
| -0.3% | -$116K | 1.92% | 13 |
|
|
2015
Q3 | $39.8M | Sell |
483,812
-1,354
| -0.3% | -$121K | 2.18% | 10 |
|
|
2015
Q2 | $42.8M | Sell |
485,166
-7,573
| -2% | -$695K | 2.14% | 11 |
|
|
2015
Q1 | $43.5M | Sell |
492,739
-10,632
| -2% | -$943K | 2.16% | 8 |
|
|
2014
Q4 | $41.8M | Sell |
503,371
-12,105
| -2% | -$1M | 2.02% | 11 |
|
|
2014
Q3 | $43.5M | Sell |
515,476
-7,274
| -1% | -$589K | 2.1% | 6 |
|
|
2014
Q2 | $42.4M | Sell |
522,750
-16,926
| -3% | -$1.33M | 2.04% | 11 |
|
|
2014
Q1 | $41.1M | Sell |
539,676
-4,649
| -0.9% | -$339K | 2.05% | 7 |
|
|
2013
Q4 | $39.2M | Sell |
544,325
-7,219
| -1% | -$502K | 1.96% | 12 |
|
|
2013
Q3 | $37.9M | Sell |
551,544
-7,368
| -1% | -$487K | 2.05% | 6 |
|
|
2013
Q2 | $35.4M | Buy |
+558,912
| New | +$36.4M | 1.95% | 12 |
|
Other funds holding NVS
Bartlett & Co's NVS Position: Q4 2023 in Review
Bartlett & Co reduced its Novartis (NVS) stake by 1.3% in Q4 2023, selling an estimated $193K and leaving 151,046 shares worth $15.1M. The position accounts for 0.25% of the portfolio, ranked #76.
Bartlett & Co first reported a position in NVS in Q2 2013 and has held it in 42 quarters since. The position peaked at $43.5M in Q1 2015. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.
- Bartlett & Co held 151,046 shares of Novartis worth $15.1M as of Q4 2023.
- Bartlett & Co sold 2,000 Novartis shares in Q4 2023, an estimated $193K.
- Novartis made up 0.25% of Bartlett & Co's portfolio in Q4 2023, its #76 holding.
- Bartlett & Co first reported a position in Novartis in Q2 2013 and has held it in 42 quarters since.
- Bartlett & Co's Novartis position peaked at $43.5M in Q1 2015.
- 1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.
Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.